Evolus (NASDAQ: EOLS) is one of 296 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Evolus to similar companies based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.
This table compares Evolus and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for Evolus and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Evolus presently has a consensus target price of $22.50, indicating a potential upside of 86.41%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.83%. Given Evolus’ stronger consensus rating and higher possible upside, research analysts clearly believe Evolus is more favorable than its rivals.
Insider & Institutional Ownership
52.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Evolus and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Evolus Competitors||$274.52 million||-$28.31 million||-30.72|
Evolus’ rivals have higher revenue, but lower earnings than Evolus. Evolus is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Evolus beats its rivals on 7 of the 11 factors compared.
Evolus Company Profile
Evolus, Inc. is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market. It offers physicians and patients a compelling value proposition with DWP-450. OnabotulinumtoxinA (BOTOX) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.